Ligand-targeted therapeutics in anticancer therapy

[1]  R. Gaspar,et al.  Use of the Post-Insertion Technique to Insert Peptide Ligands into Pre-Formed Stealth Liposomes with Retention of Binding Activity and Cytotoxicity , 2002, Pharmaceutical Research.

[2]  H. Yanagie,et al.  Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo , 2001, Pharmaceutical Research.

[3]  Ulrik B Nielsen,et al.  Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. , 2002, Biochimica et biophysica acta.

[4]  Johannes Waltenberger,et al.  In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  T. Waldmann,et al.  Vascular-Targeted Radioimmunotherapy with the Alpha-Particle Emitter 211At , 2002, Radiation research.

[6]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Saul,et al.  A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. , 2002, Cancer research.

[8]  L. Hope-Stone,et al.  Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study , 2002, British Journal of Cancer.

[9]  D. Goldenberg.  Targeted therapy of cancer with radiolabeled antibodies. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  L. Case,et al.  Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  K. Ulbrich,et al.  Differences in the intracellular fate of free and polymer-bound doxorubicin. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Ulrik B Nielsen,et al.  Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  R. Hu,et al.  Bioactivities of ricin retained and its immunoreactivity to anti-ricin polyclonal antibodies alleviated through pegylation. , 2002, The international journal of biochemistry & cell biology.

[14]  A. Frankel.  Increased sophistication of immunotoxins. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  I. Pastan,et al.  Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  D. Kerr,et al.  Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T. Kuzel,et al.  Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). , 2002, Clinical lymphoma.

[18]  E. Stadtmauer.  Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia. , 2002, Clinical lymphoma.

[19]  R. Coleman,et al.  Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Frankel,et al.  Effective targeted cytotoxicity of neuroblastoma cells. , 2002, Journal of pediatric surgery.

[21]  J. Burke,et al.  Radioimmunotherapy for acute leukemia. , 2002, Cancer control : journal of the Moffitt Cancer Center.

[22]  M. Bally,et al.  Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. , 2002, The Journal of pharmacology and experimental therapeutics.

[23]  H. Hirschberg,et al.  Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals , 2002, International journal of cancer.

[24]  M. Béhé,et al.  Retracted: Radioimmunotherapy of small‐volume disease of metastatic colorectal cancer , 2002, Cancer.

[25]  P. Low,et al.  Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs. , 2002, Biochimica et biophysica acta.

[26]  J. Leonard,et al.  Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). , 2002, Seminars in oncology.

[27]  I. Pastan,et al.  Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin. , 2002, The Journal of surgical research.

[28]  P. Conti,et al.  Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  E. Ruoslahti.  Specialization of tumour vasculature , 2002, Nature Reviews Cancer.

[30]  Zheng-Rong Lu,et al.  Design of novel bioconjugates for targeted drug delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[31]  E. Moase,et al.  ADVENTURES IN TARGETING , 2002, Journal of liposome research.

[32]  Y. Oh,et al.  pH‐sensitive, serum‐stable and long‐circulating liposomes as a new drug delivery system , 2002, The Journal of pharmacy and pharmacology.

[33]  J. Leonard,et al.  Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab). , 2002, Seminars in oncology.

[34]  C. Pennell,et al.  Designing immunotoxins for cancer therapy , 2002, Immunologic research.

[35]  P. D. de Witte,et al.  Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEG-liposomes. , 2002, International journal of oncology.

[36]  I. Lax,et al.  ‘ In vitro and in vivo studies of a VEGF 121 / rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors , 2002 .

[37]  R. Puri,et al.  Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  M. Dewhirst,et al.  The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. , 2001, Advanced drug delivery reviews.

[39]  M. Garnett,et al.  Targeted drug conjugates: principles and progress. , 2001, Advanced drug delivery reviews.

[40]  S. Batra,et al.  Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti‐tag‐72 single‐chain Fvs , 2001, International journal of cancer.

[41]  T. Ishida,et al.  Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. , 2001, Biochimica et biophysica acta.

[42]  Y. Liu,et al.  Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion. , 2001, Protein engineering.

[43]  Kreitman Rj.  Toxin-labeled monoclonal antibodies. , 2001 .

[44]  R. Brekken,et al.  Vascular endothelial growth factor and vascular targeting of solid tumors. , 2001, Anticancer research.

[45]  S. Simões,et al.  On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes. , 2001, Biochimica et biophysica acta.

[46]  P. Carter,et al.  Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.

[47]  G. Reaman,et al.  Phase I Trial of Anti-B4-Blocked Ricin in Pediatric Patients With Leukemia and Lymphoma , 2001, Journal of immunotherapy.

[48]  H. McLeod,et al.  Strategies for enzyme/prodrug cancer therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  J. Baselga.  Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials , 2001, Oncology.

[50]  J. Kopeček,et al.  Enhanced biorecognition and internalization of HPMA copolymers containing multiple or multivalent carbohydrate side-chains by human hepatocarcinoma cells. , 2001, Bioconjugate chemistry.

[51]  J. Vose,et al.  Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  R. Duncan,et al.  PDEPT: polymer-directed enzyme prodrug therapy , 2001, British Journal of Cancer.

[53]  T. Allen,et al.  In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. , 2001, Biochimica et biophysica acta.

[54]  D. Goldenberg.  The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. , 2001, Critical reviews in oncology/hematology.

[55]  J A Parker,et al.  Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2001, Critical reviews in oncology/hematology.

[56]  W. Wilson,et al.  Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. , 2001, The New England journal of medicine.

[57]  U. Nielsen,et al.  Tumor targeting using anti-her2 immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[58]  W. van Osdol,et al.  Finite element model of antibody penetration in a prevascular tumor nodule embedded in normal tissue. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[59]  I. Bernstein,et al.  Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  G. Adams,et al.  High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.

[61]  Otto C. Boerman,et al.  Radioimmunotherapy of B-cell non-Hodgkin's lymphoma , 2001, European Journal of Nuclear Medicine.

[62]  V. Torchilin,et al.  p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. , 2001, Biochimica et biophysica acta.

[63]  J. Jurcic.  Antibody therapy for residual disease in acute myelogenous leukemia. , 2001, Critical reviews in oncology/hematology.

[64]  R. Dillman.  Monoclonal antibody therapy for lymphoma: an update. , 2001, Cancer practice.

[65]  E. Sausville,et al.  The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[66]  A. Oseroff,et al.  Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  J. Vose,et al.  Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  D. Newton,et al.  Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. , 2001, Blood.

[69]  R. Dillman,et al.  Monoclonal Antibodies in the Treatment of Malignancy: Basic Concepts and Recent Developments , 2001, Cancer investigation.

[70]  T. Ishida,et al.  CORRELATIONS BETWEEN THE RATE OF INTRACELLULAR RELEASE OF ENDOCYTOSED LIPOSOMAL DOXORUBICIN AND CYTOTOXICITY AS DETERMINED BY A NEW ASSAY , 2001, Journal of liposome research.

[71]  A. George,et al.  Engineered antibodies take center stage. , 2001, Human antibodies.

[72]  C. Springer,et al.  Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. , 2001, Advanced drug delivery reviews.

[73]  R. Kreitman,et al.  Toxin-labeled monoclonal antibodies. , 2001, Current pharmaceutical biotechnology.

[74]  D. Hoessli,et al.  Anti-CD20 treatments and the lymphocyte membrane: pathology for therapy. , 2001, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[75]  E. Gautherot,et al.  Two-step targeting of xenografted colon carcinoma using a bispecific antibody and 188Re-labeled bivalent hapten: biodistribution and dosimetry studies. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[76]  M. Dewhirst,et al.  Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. , 2000, Cancer research.

[77]  J. Minna,et al.  Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. , 2000, Cancer research.

[78]  G. Denardo,et al.  Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma. , 2000, Clinical lymphoma.

[79]  R. Jain,et al.  Oncotic pressure in solid tumors is elevated. , 2000, Cancer research.

[80]  V. Ghetie,et al.  The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. , 2000, Experimental cell research.

[81]  L. Pilarski,et al.  Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. , 2000, Biochimica et biophysica acta.

[82]  E. Vitetta.  Immunotoxins and vascular leak syndrome. , 2000, Cancer journal.

[83]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[84]  J. D. White,et al.  Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  S. Steinberg,et al.  A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  E. Gautherot,et al.  Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[87]  C. Springer,et al.  Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[88]  R. Begent,et al.  Catalytic activity of an in vivo tumor targeted anti‐CEA scFv::carboxypeptidase G2 fusion protein , 2000, International journal of cancer.

[89]  E. Vitetta,et al.  The combined use of an immunotoxin and a radioimmunoconjugate to treat disseminated human B-cell lymphoma in immunodeficient mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[90]  R Pasqualini,et al.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.

[91]  C. Benz,et al.  Liposome targeting to tumors using vitamin and growth factor receptors. , 2000, Vitamins and hormones.

[92]  M. Ercan,et al.  Therapeutic radiopharmaceuticals. , 2000, Current pharmaceutical design.

[93]  A. Epenetos,et al.  Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[94]  E. Ruoslahti,et al.  An address system in the vasculature of normal tissues and tumors. , 2000, Annual review of immunology.

[95]  V. Diehl,et al.  Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin , 2000, Leukemia.

[96]  D. Papahadjopoulos,et al.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.

[97]  T. Ishida,et al.  A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs , 1999, FEBS letters.

[98]  A. Alavi,et al.  Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[99]  J. Schlom,et al.  Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[100]  T Ohlsson,et al.  Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[101]  D. Neuberg,et al.  A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[102]  M. Walker,et al.  Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. , 1999, Pharmacology & therapeutics.

[103]  F. Kraeber-Bodéré,et al.  Pretargeting with the affinity enhancement system for radioimmunotherapy. , 1999, Cancer biotherapy & radiopharmaceuticals.

[104]  J. Rizo,et al.  Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[105]  D. Tzemach,et al.  Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. , 1999, Bioconjugate chemistry.

[106]  K. Gelmon,et al.  Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  L. Pilarski,et al.  Cellular Trafficking and Cytotoxicity of Anti-Cd19-Targeted Liposomal Doxorubicin in B Lymphoma Cells , 1999 .

[108]  S. O’Day,et al.  Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[109]  T M Allen,et al.  In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. , 1998, Cancer research.

[110]  D. Stuart,et al.  CHAPTER 4.6 – Targeted sterically stabilized liposomal drug delivery , 1998 .

[111]  D. Papahadjopoulos,et al.  Medical applications of liposomes , 1998 .

[112]  P. Low,et al.  Folate-targeted liposomes for drug delivery , 1997 .

[113]  E. Moase,et al.  Therapeutic opportunities for targeted liposomal drug delivery , 1996 .

[114]  P. McCarthy,et al.  A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease. , 1996, Transplantation.

[115]  J. Rosenecker,et al.  Increased liposome extravasation in selected tissues: effect of substance P. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[116]  R. Straubinger,et al.  Antitumor Efficacy of Taxane Liposomes on a Human Ovarian Tumor Xenograft in Nude Mice , 1995 .

[117]  E. Moase,et al.  Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. , 1995, Biochimica et biophysica acta.

[118]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[119]  R. Straubinger,et al.  Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. , 1995, Journal of pharmaceutical sciences.

[120]  C. Springer,et al.  Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. , 1994, Methods and findings in experimental and clinical pharmacology.

[121]  R. Jain,et al.  Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.

[122]  M. Bally,et al.  Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. , 1994, Cancer research.

[123]  J. Weinstein,et al.  Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. , 1992, Cancer research.

[124]  K. Johnson.  An Update. , 1984, Journal of food protection.

[125]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[126]  H. Meessen.  [Pathology of therapy]. , 1958, Therapie der Gegenwart.